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Millions of patients worldwide suﬀer from end-stage liver pathologies, whose only curative therapy is liver transplantation (OLT).
Given the donor organ shortage, alternatives to OLT have been evaluated, including cell therapies. Hepatocyte transplantation has
been attempted to cure metabolic liver disorders and end-stage liver diseases. The evaluation of its eﬃcacy is complicated by the
shortage of human hepatocytes and their diﬃcult expansion and cryopreservation. Recent advances in cell biology have led to the
concept of “regenerative medicine”, based on the therapeutic potential of stem cells (SCs). Diﬀerent types of SCs are theoretically
eligible for liver cell replacement. These include embryonic and fetal SCs, induced pluripotent cells, annex SCs, endogenous liver
SCs, and extrahepatic adult SCs. Aim of this paper is to critically analyze the possible sources of SCs suitable for liver repopulation
and the results of the clinical trials that have been published until now.
1. Cell Therapies for LiverDiseases
Liver pathologies aﬀect hundreds of millions of patients
worldwide. The most common causes of hepatopathy are
chronic hepatitis C and B, alcoholism, nonalcoholic fatty
liver disease, autoimmune, and drug-induced hepatic disor-
ders. Many of these conditions can be prevented or treated,
butifnot,theycanleadtoprogressiveliverinjury,liverﬁbro-
sis and ultimately cirrhosis, portal hypertension, liver failure,
and,insomeinstances,cancer.Therearecurrentlymorethan
5 million people in the United States suﬀering from end-
stage liver pathologies, whose only curative therapy is liver
transplantation (OLT). More than 5,000 liver transplants are
performed in the United States each year (including more
than 500 in children). About 20,000 people are waiting for
OLT, but only 7,000 transplants are performed annually and
as many as 1,500 patients die yearly while on the waiting list
[1].
Given the donor organ shortage, various alternatives to
OLT have been evaluated, such as split-liver and related
living-donor liver transplantation. These procedures are
still limited by the donor scarcity, the high costs, and
the lifelong immunosuppressive treatments that they all
require [2, 3]. Thus, the development of cell therapies for
the treatment of end-stage hepatic diseases is currently
under investigation all over the world. A cell therapy can
be deﬁned as “the use of living cells to restore, maintain,
or enhance tissue and organ function” [4]. Cell therapies
in hepatology have numerous potential advantages when
compared to OLT, since transplantable cells can be (1)
in vitro expanded and cryopreserved, abolishing the limit
of organ shortage; (2) genetically manipulated, to correct
inborn errors of metabolism; (3) cryopreserved for future
use;(4)infusedwithoutmajorsurgery;(5)obtainedfromthe
same patient, avoiding risk of rejection and need for lifelong
immunosuppression [5].
One possible cell therapy source to restore the liver
functional mass is represented by adult hepatocytes, that
represent a particularly appealing tool, because they are
mature and fully functional hepatic cells. Since the ﬁrst
successful hepatocyte transplantation in a rodent model
of Crigler-Najjar syndrome, many preclinical studies and2 Stem Cells International
clinical applications of this technique have been made to
cure metabolic liver disorders and end-stage liver diseases
[6]. In most instances, hepatocyte transplantation has been
able to grant a clinical improvement for up to 12 months
[7]. In patients with liver failure, hepatocyte-based therapies
have also included the use of human or porcine hepatocytes
in bioartiﬁcial liver devices [8]. Despite some encouraging
results, the interpretation of these studies is hampered by
the limited number and heterogeneity of patients, the lack
of controls, the variety in terms of experimental design, out-
come parameters, and follow-up duration. The evaluation
of the eﬃcacy of hepatocyte transplantation and bioartiﬁcial
liver support systems is further complicated by the shortage
of human hepatocytes. Indeed, it is ethically diﬃcult to
assign cadaveric livers to these experimental protocols, while
many patients still die on the OLT waiting list. Moreover,
primary cultured hepatocytes are hard to expand in vitro and
cryopreserved cells are easily damaged during the freezing-
thawing procedure. As a consequence, alternative solutions
are being examined in the hepatic cell therapy ﬁeld. Among
these, of particular interest is the so-called “regenerative
medicine”, based on the therapeutic potential of stem cells
(SCs) [5, 9].
SCs are undiﬀerentiated cells, able to give rise to diverse
mature progenies and to self-renew, through the alternation
of symmetrical and asymmetrical divisions. SCs exist in all
multicellular organisms and play a central role in tissue
genesis, regeneration, and homeostasis, by providing new
elements to increase tissue mass during pre- and postnatal
growth, and by replacing cell loss due to senescence or dam-
age [10, 11]. SCs possess a hierarchy of potentialities: from
the totipotency of the zygote and its immediate progeny,
to the pluripotency of embryonic stem cells (ESCs), to the
multi/unipotency of tissue-speciﬁc adult SCs (ASCs). The
latter persist in terminally diﬀerentiated tissues, allowing for
their renewal and regeneration [12–15]. SCs colocalize with
supporting cells in a physiologically limited and specialized
microenvironment, or “niche”, that varies in nature and
location depending upon the tissue type [16]. The recipro-
cal interactions between SCs and their microenvironment,
through cell-cell and cell-matrix connections as well as the
secretion of soluble factors, inﬂuence SC behavior [17, 18].
SCs are already leaving the bench and reaching the
bedside, despite an incomplete knowledge of the genetic
control program driving their fate and plasticity [5]. In
hepatology, the ﬁrst attempts to translate SC basic research
into new clinical strategies have been made. Aim of this
review is to summarize the state of the art on SC-based
therapies in hepatology. In particular, we will discuss the
possible sources of SCs suitable for liver repopulation and
will highlight both the beneﬁts and the potential risks of
these new tools for the treatment of liver pathologies.
2. Embryonic, Fetal, andAnnex Stem Cells
2.1. Embryonic and Fetal Liver Stem Cells. ESCs and their
derivatives might constitute an easily available source to
obtain a large number of transplantable cells for regenerative
treatments. ESCs are pluripotent cells derived from the inner
cellmassoftheblastocystandcangenerateanydiﬀerentiated
phenotype of the three primary germ layers (endoderm,
mesoderm, and ectoderm), as well as germ cells [15]. ESCs
can be indeﬁnitely maintained in an undiﬀerentiated state,
though they seem to develop karyotypic abnormalities over
long periods in culture [5]. It has been demonstrated that
ESCs can diﬀerentiate in vitro towards the hepatic lineage by
simple removal of factors that prevent their diﬀerentiation,
and/or through the exposure to appropriate growth factors,
as reviewed elsewhere [7, 19]. Moreover, in several animal
models of hepatic disease, ESC-derived hepatocyte-like cells
were able to colonize the injured liver and function as
mature hepatocytes [7, 19]. Fetal liver SCs, also named
“hepatoblasts”, appear when the hepatic endoderm has
been speciﬁed and the liver bud is growing. Hepatoblasts
are bipotent, being able to give rise to both hepatocytes
and bile duct cells, and coexpress biliary and hepatocytic
markers, such as albumin, alpha-fetoprotein (AFP), and
CK19. Studies in diverse model organisms have revealed
evolutionarily conserved inductive signals and transcription
factor networks that elicit the diﬀerentiation of liver SCs,
as reviewed elsewhere [19]. Murine hepatoblast cell lines
have been established by various research groups and their
capacity to repopulate the liver upon transplantation in
animal models has been extensively proved, as discussed
elsewhere [20]. In contrast to adult liver, ESCs and fetal liver
SCs are thought to be highly proliferative, less immunogenic
and more resistant to cryopreservation. However, ethical
issues and the possibility of immune rejection and ter-
atoma/teratocarcinoma formation in the recipients explain
why their use is currently reserved to preclinical studies
[21].
2.2. Induced Pluripotent Stem Cells. The recently described
induced pluripotent stem cells (iPSs) might circumvent
the ethical concerns and the risk of rejection related to
embryonic and fetal liver SCs. Indeed, iPSs are embryonic-
like SCs derived from somatic cells by forced expression
of reprogramming factors (Oct3/4 and Sox2 along with
either Klf4 or Nanog and Lin28). Theoretically, iPSs could
be obtained from the same patient and used for tissue
replacement or gene therapy. It is not yet clear how precisely
the known developmental signals must be orchestrated to
properly program hepatic cells at will, but detailed studies of
the activated signaling pathways and their cross-regulatory
interactions during embryogenesis will be informative. The
ﬁrst step of hepatic development from iPSs is the induction
of deﬁnitive endoderm by using activin A. Further treatment
with BMP-4 and bFGF can then direct cells towards the
hepatic lineage [19]. Nowadays, iPS-based cell therapies
have been applied in several animal models of pathologies,
with encouraging results, and human iPS cells have been
demonstrated to possess a hepatocyte-lineage diﬀerentiation
potential comparable to that of ESCs [22]. Even if some
limitations still remain (i.e., the potential for teratoma
formation), iPS-derived hepatocytes are a very promising
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2.3. Annex Stem Cells. Another promising source for SC-
based treatments in hepatology may be represented by cells
established from placental/cordonal tissues, which do not
seem to form teratomas or teratocarcinomas in humans,
and have higher proliferation and diﬀerentiation potential
than ASCs. Several studies indicated that umbilical cord and
umbilical cord blood, placenta and amniotic ﬂuid are an
easily accessible source of pluripotent SCs, which may be
readily availablefor transplantation, or forfurther expansion
and manipulation prior to cell therapies [18, 23]. These cells
can be extensively expanded without loss of potency and
haveabroaddiﬀerentiationpotential,sincetheycangenerate
progenies of all three germ layers. These pluripotent annex
SCs can be forced to diﬀerentiate into hepatocyte-like cells
in vitro and are capable of liver repopulation in vivo,u p o n
transplantation in animal models [7, 24]. We demonstrated
that human umbilical cord blood SCs were able to colonize
the liver and diﬀerentiate into hepatocytes after acute toxic
liver damage in NOD/SCID mice and in immunocompetent
rats [25, 26]. Moreover, microarray analysis led us to the
identiﬁcation of genes whose modulation strongly correlated
with a more eﬃcient process of liver repair after SC
injection, proving the ability of these cells to positively
inﬂuence the hepatic microenvironment and enhance the
endogenous hepatic regeneration process [27]. The plasticity
and accessibility of cord blood SCs have given the rationale
for the creation of cord blood unit banks, where these cells
can be collected and stored for future use.
3. Endogenous Adult Liver
Stem/Progenitor Cells
Regenerative processes in postnatal liver parallel those
occurring in development and involve populations of SCs
and progenitor cells that can be identiﬁed by anatomic,
antigenic, and biochemical proﬁles [28]. In particular, the
liver has an extensive regenerative potential in response to
parenchymal loss, mainly granted by mature hepatocytes,
whichcanre-enterthecellcycletorestorethelivermass.This
is a very eﬃcient system and, after 2/3 partial hepatectomy
(PH)inrats,proliferationofhepatocytesandcholangiocytes,
followed by stellate and endothelial cells, can regrow the
remnant to the original mass in less than 2 weeks [29].
However, whenever the replication ability of hepatocytes is
experimentally inhibited or impaired by advanced chronic
injury, liver regeneration can still be accomplished by the
activation, expansion, and diﬀerentiation of the so-called
“hepatic progenitor/stem cells”. These cells are thought to
be responsible for the human ductular reaction, which
corresponds to the oval cell activation seen in speciﬁc rodent
models of liver injury [30].
The term “oval cells” (OCs) was introduced to describe
small proliferating cells with oval nuclei observed in rat
livers following certain carcinogenic regimens [17, 31, 32].
OCs are an extremely heterogeneous population, which
includes various fractions with diﬀerent stemness poten-
tial, depending upon the experimental protocol and the
animal model under investigation [33]. OCs are bipotent
(able to give rise to both cholangiocytes and hepatocytes)
and coexpress biliary and hepatocytic markers, such as
CK19, alpha-fetoprotein, and albumin [34]. Over the past
thirty years, several studies have described the isolation,
culture diﬀerentiation and in vivo transplantation of liver
OCs. A variety of surface antigens—including OV6, CD44,
EpCAM and hematopoietic markers (i.e., CD34, CD133,
c-kit)—have been used to identify and isolate OCs, as
reviewed elsewhere [5, 28, 35]. Recently, Grompe’s group
has generated a new collection of monoclonal antibodies by
immunization of Fischer rats with enzymatically dispersed
nonparenchymal cells from the livers of adult mice treated
with 3,5-diethoxycarbonyl-1,4-dihydrocollidine, to produce
cell surface reactive reagents more speciﬁc for the oval
cell response. Diﬀerential activity was observed on normal
liver cells and at diﬀerent stages of oval cell activation,
indicating potential utility for progenitor cell identiﬁcation
[36]. Recently, Kamiya et al. were able to enrich and
culture CD133+/CD13+/CD49f+ bipotent progenitor cells
from noninjured postnatal livers [37], while Sackett et al.
have proposed the winged helix transcription factor Foxl1 as
a potential marker of OCs in mice [38].
In humans, the counterpart of OCs is represented by the
intermediate hepatobiliary cells, or ductular hepatocytes, or
hepatic progenitor cells (HPCs), which can be seen in several
hepatopaties, such as chronic cholestasis, submassive necro-
sis, alcoholic liver disease, focal nodular hyperplasia, and
liver allograft failure [39]. In such conditions, intermediates
between hepatic SCs and hepatoblasts and between hepato-
blasts and adult parenchyma are observed and ampliﬁcation
of one or both pluripotent cell subpopulations can occur
[28]. A frequent trigger of ductular reaction is the presence
of chronic damage, resulting in hepatocyte senescence. Like
OCs, HPCs are bipotent, coexpress biliary and hepatocytic
markers, and also express hematopoietic progenitor cell
antigens [40, 41]. In the last years, numerous studies
have been published on the isolation, characterization and
diﬀerentiation of putative liver progenitor cells from human
livers, but the identiﬁcation of a speciﬁc marker of HPCs
awaits further investigation [5, 33, 37, 42–44].
Overall, whether OCs/HPCs fulﬁl the criteria to be
considered true LSCs is still controversial. Some authors
believe that OCs and HPCs may represent transit-amplifying
cells derived from a more primitive LSC [32]. Given the
diﬃculty of identifying unique LSC markers, it has been
suggested to consider stem-cellness as a function instead of
an entity: marking resident SCs based upon their quiescence
might diﬀerentiate true SCs from their rapidly dividing
derivatives [5]. By using a label-retention assay following
acetaminophen-induced liver injury in mice, Kuwahara et al.
found 4 possible LSC populations [45]: (a) replicating hep-
atocytes at the parenchymal/stromal interface; (b) ductular
cells of the canal of Hering (CoH); (c) cholangiocytes of the
intralobularbileducts;and(d)periductularnullcells(devoid
of hepatocytic and biliary markers). The asymmetrically
dividing cells that populate these sites might represent
some form of lineage hierarchy within the LSC population:
periductular null cells might give rise to the cytokeratin-
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to the intraductular cells and periductular hepatocyte-like
cells [46]. Recently, De Alwis et al. have demonstrated that
regenerating hepatocytes arise from a LSC population in the
CoH and move outward into the liver parenchyma, as in
the streaming liver hypothesis. Interestingly, this observation
seems to indicate that the LSC population is active also in
healthyliversandcontributestothehepaticturnover[47].In
conclusion, LSC participation to hepatic repair is probably
more complicated than in organs with normally rapid cell
turnover and multiple liver cell populations might function
as LSCs, depending on severity, location, and chronicity of
injury.
The existence of multiple populations of liver cells
with stemness potential implies the existence of multiple
LSC niches, that can be activated depending upon the
mechanism and location of injury [45, 46]. Presumably, the
damagedliverreleasesmoleculesthatstimulatetheactivation
of OCs/HPCs and mediate their subsequent proliferation,
migration and diﬀerentiation into mature hepatic pheno-
types. Up to date, an extensive number of growth factors
and cytokines which regulate the various phases of the
OCs/HPCs response have been described, including SCF,
HGF, EGF, FGF, Hedgehog and Wnt signalling pathways,
SDF-1/CXCR4 axis, tumor necrosis factor, interleukin-6,
interferons, transforming growth factors, and transforming
growth factor like weak inhibitor of apoptosis (TWEAK)
[48, 49]. Noteworthy, the responses of OCs/HPCs to HGF
via cMet and the potential autocrine loops with TGF-
alpha, EGF and FGF are similar to the patterns expressed
by hepatocytes during liver regeneration, despite the fact
that hepatocytes and LSCs do not tend to proliferate
contemporaneously. This might be due to the modulatory
eﬀects of inﬂammatory cells within the niche, producing a
range of cytokines and chemokines (such as TWEAK, TGF-
beta and INF-gamma) that could inﬂuence the LSC response
[50].Anothermoleculeofgrowinginterestintheﬁeldofliver
regeneration is the granulocyte-colony stimulating factor
(G-CSF), a cytokine involved in mediating hematopoietic
stem cells (HSCs) mobilization from the bone marrow
(BM) into the peripheral blood [51]. In the last decade,
several studies have indicated that G-CSF may be eﬀective in
mobilizing BM cells that contribute to liver repair [5, 51].
In 2007, we elucidated the double mechanism of action
of G-CSF during OC-mediated liver regeneration in rats:
G-CSF is able to contribute to liver repair by increasing
the BM-derived liver repopulation (vide infra), and also by
activating the endogenous OCs, that express G-CSF receptor
(G-CSFR) [52]. The upregulation of G-CSFR subsequent
to G-CSF administration has been recently observed in
a small-for-size liver model, conﬁrming a direct receptor-
mediated eﬀect of G-CSF on the hepatic parenchyma [53].
These data expand the knowledge regarding the spectrum
of actions of G-CSF on ASCs [51, 52]. In fact, it has been
demonstrated that G-CSF and its receptor are widely present
in neurons and adult neural stem cells. This expression
is induced by ischemia, and both counteracts neuronal
degeneration and contributes to long-term plasticity after
damage. Similarly, G-CSF administration following myocar-
dial infarction in mice induces G-CSFR expression in
cardiomyocytes and results in the prevention of cardiac
remodeling.
In summary, despite the eﬀorts toward the characteriza-
tion of human LSCs and of their niches, in view of a possible
useforcelltherapies,themicroenvironmentalfactorsdriving
LSC fate and LSCs themselves need to be univocally deﬁned
prior to attempting any clinical application. The identiﬁ-
cation of endogenous LSCs and of the signals that govern
their proliferation and diﬀerentiation to mature hepatocytes
might lead to the development of clinically feasible methods
to induce liver repopulation from these endogenous cells
and/or to allow maturation of stem/progenitor cells to
hepatocytes in vitro and in vivo.
4.ExtrahepaticAdultStemCellswith
Hepatogenic Potential
Liver regeneration is mainly an endogenous process, driven
by hepatocytes and resident hepatic stem/progenitor cells.
However, it has been observed that certain populations of
extrahepatic ASCs can migrate into the liver and contribute
to its repopulation and turnover [5]. A particularly high
degree of plasticity has been shown by bone marrow
stem cells (BMSCs), which can give rise to a wide range
of phenotypes, including hepatocyte-like cells. Since the
pioneering study by Petersen et al. in 1999 [54], numerous
reportsandreviewshavebeenpublishedonBMcontribution
to liver regeneration, often with contradictory conclusions
[23, 55, 56]. It is generally agreed that BM represents a
possible source of LSCs, even if the frequency of colo-
nization, in the absence of a strong selective pressure, is
very low, unlikely suﬃcient per se to achieve a signiﬁcant
contribution to hepatic repopulation. However, the few
BM-derived cells which do engraft may play an important
role in modulating the endogenous repair mechanisms
within the hepatic stem cell niche [5, 27, 57]. As clearly
demonstrated by Petersen’s and our group in 2007, BMSCs
may or may not play a critical role in liver regeneration,
depending upon the experimental setting [58]. Based on
the already cited model of lineage hierarchy within the LSC
population [46], we can postulate that the periductular null
cells might, at least in part, originate from extrahepatic
SCs of BM origin and then give rise to the ductular
cells of the CoH. These cells, in turn, can diﬀerentiate
into intraductular cells and periductular hepatocyte-like
cells.
Regarding the mechanisms underlying BMSC plasticity,
upon engraftment BMSCs might either transdiﬀerentiate
into parenchymal cells or fuse with resident cells in the host
tissue. Fusion phenomena between BMSCs and other cell
types (i.e., Purkinjie cells, cardiomyocytes and hepatocytes)
have been shown both in vitro and in vivo [5]. Cell fusion is
a physiological phenomenon in certain districts, such as liver
and muscle, and it may or may not play a prominent role
in SC plasticity, depending on the model of injury and the
host phenotype [59]. It has been also proved that fusion and
transdiﬀerentiation can coexist and produce therapeutically
beneﬁcial results [60, 61].Stem Cells International 5
In order to initiate a BM response, the injured liver must
signal to the responding cell types. A pivotal role in BMSC
recruitmentisplayedbySDF-1.BM-derivedliver-committed
SCs expressing SDF-1 receptor (CXCR4) are present in
the peripheral blood and may colonize the damaged liver
by following a SDF-1 gradient [62, 63]. Other molecules
secreted by the injured hepatic milieu that can contribute
to BMSC recruitment and homing into the liver are the
hepatocyte growth factor (HGF), some ﬁbrosis mediators,
such as matrix metalloproteinase-9 (MMP9), and the G-
CSF [64–66]. The mechanisms underlying the adhesion and
retention of BMSCs to human liver compartments have been
only in part elucidated [67].
Adult BM comprises two main populations of ASCs able
to convert into hepatic cells, either by fusion or transdiﬀer-
entiation:hematopoieticSCs(HSCs)andmesenchymalstem
cells (MSCs).
HSCs are responsible for the renewal of blood cells and
canbealsoisolatedfromumbilicalcordbloodandperipheral
blood. It is generally accepted that the most primitive and
long-term human HSCs are characterized by the expression
of CD133, Thy1 (CD90) and VEGFR2 and by a variable
expression of CD34 and CD38 [68]. BM-resident HSCs
can be mobilized into the peripheral blood under speciﬁc
stimuli such as tissue injury or administration of G-CSF
[5]. Mobilized HSCs can colonize extramedullar sites and
participate to their regeneration, by promoting the immune
response and/or by transdiﬀerentiating into ASCs within
peripheral tissues [5, 18, 62].
MSCs, also called stromal stem cells, mesenchymal pro-
genitors, mesenchymal stromal cells, colony-forming unit-
ﬁbroblastic cells, are highly proliferating, adherent cells, that
reside in a perivascular BM niche and also in the wall of
blood vessels within most organs [69]. Numerous studies
have demonstrated that MSCs are able to diﬀerentiate
into a variety of mesodermal cell lineages (osteoblasts,
chondroblasts, adipocytes, myocytes, and cardiomyocytes),
as well as nonmesodermal cells (such as hepatocytes and
neurons), depending upon the microenvironment in which
they reside [70]. MSCs might become a more suitable
source for SC-based therapies than HSCs, because of their
immunological properties: MSCs are less immunogenic and
can induce tolerance upon transplantation [71]. Moreover,
MSCs showed the highest potential for liver regeneration
compared with other BM cell subpopulations in an animal
model of hepatic injury [72].
A more recently identiﬁed SC population within the
BM,theso-calledmultipotentadultprogenitorcells(MAPCs),
seems to be endowed with an impressive plasticity and has
shown liver diﬀerentiation potential both in culture and in
animal models [57]. These cells could potentially copurify
with HSCs or MSCs and contaminate these cell populations
investigated in liver repopulation studies. According to this
hypothesis, rather than being a source of liver-committed
SCs, BM could act as a hide out for recirculating pluripotent
SCsthatmightbedepositedearlyduringdevelopmentinBM
and could be a source for tissue/organ regeneration [62, 73].
Therefore, the present distinction between HSCs and MSCs
may become obsolete, given the heterogeneity and possible
overlaps of these various BMSC populations, which could
share a common stem cellness core [5].
As a closing remark, it is worth a note that adipose
tissue has been reported as a rich source of easily accessible
MSCs (adipose tissue stromal cells, ATSCs) capable of hepatic
diﬀerentiation in vitro and in vivo [74, 75]. ATSCs are similar
to BM-MSCs in terms of surface antigen marker proﬁle and
diﬀerentiation potential, and ATSCs have been reported to
exert an even higher proliferative capacity in vitro [76, 77].
We have recently achieved the hepatogenic conversion of
ATSCs, using a two-step protocol with sequential addition
of growth factors. In order to understand the molecular
events involved in ATSC hepatic transdiﬀerentiation, the
full genome expression proﬁles of ATSC-derived hepatocyte-
like cells versus undiﬀerentiated ATSCs were compared. We
identiﬁed several targets that depict the numerous biological
functions exerted by the liver, including protein metabolism,
innate immune response regulation, and biodegradation
of toxic compounds. Moreover, we showed that ATSC
diﬀerentiation into hepatocyte-like cells might be caused by
a mesenchymal-to-epithelial transition [78].
Overall,despiteanincompleteknowledgeoftheirbiolog-
ical properties, the plasticity and accessibility of HSCs and
MSCs from BM and adipose tissue render these ASCs an
attractive tool for the regenerative medicine.
5.StemCell-Based Therapies inHepatology
As previously discussed, diﬀerent types of SCs with hepatic
diﬀerentiation potential are theoretically eligible for liver
cell replacement. These include ESCs, iPSs, hepatoblasts,
annex SCs, and adult SCs, such HPCs, HSCs, and MSCs.
Despite encouraging results in vitro, the use of hepatocyte-
like cells derived from these stem/progenitor cell populations
is still conﬁned to preclinical studies, given the scarce
tissue-speciﬁc functionality and, up to now, the lack of
evidenceofstrongliverrepopulationlevelsinanimalmodels.
Nowadays,themostpromisingsourceforSC-basedtherapies
is represented by the intraportal or intrahepatic infusion of
freshly isolated or in vitro expanded HSCs [79]. Another
appealing option is represented by the administration of
mobilizing/proliferating agents, such as G-CSF, that is able
to both enhance the HSC mobilization into the peripheral
blood and facilitate the endogenous LSC activation [5]. G-
CSFadministrationcouldalsoexertbeneﬁcialimmunomod-
ulatory eﬀects in presence of liver failure, since it can reverse
the neutrophil defects and the status of immune paralysis
associated with severe hepatic insuﬃciency [49, 50, 80].
5.1. Bone Marrow Stem Cell Transplantation. BMSCs seem
to be physiologically involved in liver repair in humans. A
spontaneous mobilization of CD34+ cells has been reported
following liver resection in patients with primary liver cancer
or metastasis [81]. Similarly, a signiﬁcant increase in the
percentage of CD133+ cells has been found by Gehling et al.
in blood samples of healthy living liver donors and further
in vitro investigations have demonstrated that the mobilized
cells were indeed liver committed [82]. Recently, the same6 Stem Cells International
authors observed that liver cirrhosis is associated with an
intermittent mobilization of various populations of liver-
committed cells of putative BM origin into the circulation
[83].
ThepossibletherapeuticinterestofBMSCsinhepatology
was ﬁrstly investigated in 2005: intraportal autologous
transplantation of CD133+ BMSCs in patients with liver
cancer undergoing portal embolization before extensive liver
resection (LR) achieved some clinical improvement [84].
Similar results were obtained two years later by F¨ urst et al.
who concluded that in patients with malignant liver lesions a
combinationofportalveinembolizationandCD133+ BMSC
administration increased the degree of hepatic regeneration
in comparison with embolization alone [85]. In 9 patients
with cirrhosis, who received portal vein infusion of unsorted
autologous BMSCs, an improvement in Child-Pugh score
and albumin levels was reported [86]. Recently, a signiﬁcant
increase of liver function postLR has been documented
in patients with cirrhosis and hepatocellular carcinoma,
following autologous BMSC transplantation prior to surgery
[87]. So far, only one negative result regarding BMSC-
therapies for end-stage liver disorders has been reported: in
a phase-I clinical trial on decompensated cirrhotic patients,
the infusion of autologous CD34+BM cells through the
hepatic artery was unsafe and ineﬀective in improving the
liver function [88].
5.2. Circulating Hematopoietic Stem Cell Mobilization, Collec-
tionandReinfusion. OtherSC-basedtherapiesinhepatology
have been based upon the collection from peripheral blood
by leukapheresis and subsequent reinfusion of circulating
HSCs, mobilized by G-CSF administration. The feasibility,
safety, and pattern of BMSC mobilization with G-CSF
in patients aﬀected by cirrhosis has been evaluated [89].
Yannaki et al. described boost infusions of mobilized CD34+
cells after a standard G-CSF regimen in two patients. The
procedure was safe, well tolerated and associated with a
lasting amelioration in the clinical course of the disease
during the follow-up (1 month) [90]. A signiﬁcant bio-
chemical and histopathological improvement was achieved
by intraportal administration of mobilized CD34+ BMSCs
following G-CSF exposure in one patient aﬀected by drug-
induced acute liver failure [91]. In a phase-I clinical trial
on 5 patients with acute on chronic liver failure, G-CSF
administration, followed by collection and intraportal or
intrahepaticreinfusionofcirculatingCD34+ cells,resultedin
animprovementofthehepaticfunctioninmorethan50%of
the cases, without signiﬁcant side eﬀects during a follow-up
of 60 days [92]. The same patients were then monitored for
up to 18 months: the procedure was safe in short and over
long term, by absence of tumor formation and the beneﬁcial
eﬀects lasted around 12 months [93]. Recently, in 9 patients
with alcohol-related cirrhosis, the reinfusion into the hepatic
artery of CD34+ BM-derived cells, collected after G-CSF
mobilization and in vitro expanded, was well-tolerated and
produced a clinical and biochemical improvement [94].
In another trial, a total of 40 patients with HBV-related
cirrhosis were randomized to receive G-CSF alone or in
combination with leukapheresis and reinfusion of peripheral
blood monocytes into the hepatic artery. During a follow-
up of 6 months, a signiﬁcant biochemical and clinical
improvement was observed in both groups, even though
the subjects receiving G-CSF plus SC infusion obtained the
greater and longer-lasting beneﬁcial eﬀects [95].
5.3. G-CSF Treatment. Given its beneﬁcial role in hepatic
regeneration, G-CSF alone has been employed for the
treatment of end-stage liver diseases in humans. Gaia et
al. treated 8 patients aﬀected by severe liver cirrhosis with
G-CSF 5μg/Kg bid for three days: the treatment was well
tolerated in all patients during a follow-up of 8 months,
and a mobilization of BMSCs coexpressing epithelial and
stem markers was noted [89]. Our group administered G-
CSF (5 or 15microgr/Kg/day) for 6 days to 24 patients
with severe liver cirrhosis. This procedure was safe, resulted
in a dose-dependent mobilization of BMSCs, but did not
achieve any signiﬁcant clinical improvement [96]. Similarly,
Lorenzini et al. treated 18 nondecompensated cirrhotic
patients with G-CSF, obtaining a good CD34+/CD133+ cell
mobilization, despite the absence of clinical improvement
[97]. Spahr et al. recently published the largest randomized
trial, conducted on 24 patients with alcoholic cirrhosis,
randomized to standard care associated with G-CSF or
standard care alone. G-CSF was safe and able to mobilize
CD34+ cells and increase HGF; however, the study was
too small to make any comment regarding survival or
eﬃcacy. Interestingly, G-CSF was associated with the induc-
tion of HPC proliferation within 7 days of administration
[98].
Most of the above-mentioned clinical trials share com-
mon limits, being conducted on small groups of patients,
without controls, and using outcome parameters easily
subjected to be biased, as reviewed elsewhere [5, 7, 23, 99–
103]. Overall, the use of BMSCs for the treatment of end-
stage liver diseases holds several advantages, such as easy
accessibility, unlimited supply and no risks of rejection or
need for immunosuppressive therapies, when autologous
cells are employed. Nonetheless, some conceptual issues
still limit the diﬀusion of such treatments in the clinical
practice.
(1) On the basis of the previously reported preclinical
data, BM cells seem to facilitate liver regeneration
mainly by a microenvironment modulation, which
is likely to be transitory. In such a case, multiple
treatments would presumably be required to achieve
signiﬁcant and lasting clinical results; technical issues
that need to be addressed regard the surface antigens
used for HSC puriﬁcation, the route of delivery, the
amount of infused cells and the timing of infusions.
(2) It is not clear at present whether mobilization with
G-CSFwithoutleukapheresisandreinfusion ofHSCs
would suﬃce to gain a signiﬁcant clinical beneﬁt.
Moreover, G-CSF therapies need to be standardized
intermsofdosage,timing,andeventuallyassociation
with other cytokines or interventions.Stem Cells International 7
(3) Thepossibilityofcellfusionandtheriskofmalignant
transformation of the transplanted cells, especially if
in vitro pre-expanded before reinfusion, cannot be
excluded and impose a careful evaluation and longer
follow-up periods for assessing the safety and eﬃcacy
of SC-based treatments.
(4) BMSCs have the potential to diﬀerentiate into
endothelial cells and ﬁbroblasts within the liver,
and, as such, they might exert a proﬁbrogenic eﬀect
[57]. Therefore, it is mandatory to examine the
involvement of the infused SCs in the reconstitution
of hepatic nonparenchymal cells.
Until these open questions can be properly answered,
through an intense collaborative eﬀort from basic cell
biologists, translational scientists and clinicians, SC-based
therapies for liver diseases should be limited to well designed
and adequately powered clinical trials.
6. Conclusions
SCs are promising tools at the service of regenerative
medicine for the treatment of degenerative disorders, inborn
errors of metabolism, and organ failure. In hepatology,
the ﬁrst attempts to translate SC basic research into new
clinical strategies for the treatment of acute and chronic
hepatopathies have been made. In particular, HSCs trans-
plantation and G-CSF infusion are an attractive option
for the treatment of end stage liver pathologies, as we
already handle G-CSF and transplant HSCs in clinics, for
hematologic and oncologic disorders. Right now, the major
role for stem cell therapy is as a bridge to transplantation or
as a way of maintaining those patients who are not eligible
for OLT. Nonetheless, critical aspects need to be further
addressed, including the long-term safety, tolerability, and
eﬃcacy of these SC-based treatments, as well as their
carcinogenic potential. As a consequence, it is paramount
to conduct larger and well-designed clinical trials to fully
establish the safety proﬁle of such therapies and to deﬁne the
target patient groups with eﬃcacy assessed by standardised
protocols.
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